Trial Profile

Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson's Disease Patients

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 16 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Levodopa/carbidopa (Primary)
Indications Parkinson's disease
Focus Therapeutic Use
Acronyms ELEVATE-PD
Sponsors IMPAX Laboratories

Most Recent Events

05 Dec 2025 According to a Amneal Pharmaceuticals, longer-term data from this trial is expected in 2026.
05 Dec 2025 Interim Results published in the Amneal Pharmaceuticals media release.
05 Dec 2025 According to a Amneal Pharmaceuticals media release, interim data from this trial was presented at the Parkinsons Study Group (PSG) Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com